Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics Q3 2026 net loss narrows to $8.0 million from $10.1 million

Positive Impact 3 of 5 earnings Written later

Elicio Therapeutics reported third quarter 2026 results on November 5, 2026, with a net loss of $8.0 million, down from $10.1 million a year earlier. The company said its cash and cash equivalents of $30.9 million as of September 30, 2026 will support operations into the second quarter of 2027, and it discussed Phase 2 AMPLIFY-7P results that did not meet the primary disease-free survival endpoint in the intent-to-treat population.

Key points

  • Net loss was $8.0 million, or $0.30 per share, versus $10.1 million, or $0.60 per share, in the third quarter of 2025.
  • R&D expense was $4.9 million versus $5.0 million; G&A expense rose to $3.6 million from $3.0 million.
  • Cash and cash equivalents were $30.9 million at September 30, 2026, with an expected runway into the second quarter of 2027.
  • AMPLIFY-7P missed its primary DFS endpoint in the intent-to-treat population; pre-specified subgroup analyses showed risk reductions of 49% and 43% in ctDNA-negative and ctDNA-positive patients.

The filing

CompanyElicio Therapeutics, Inc. (ELTX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:12 PM ET
Accession number0001601485-26-000065

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.